Halozyme Therapeutics Inc...

NASDAQ: HALO · Real-Time Price · USD
67.28
1.74 (2.65%)
At close: Aug 15, 2025, 3:59 PM
67.27
-0.01%
After-hours: Aug 15, 2025, 04:10 PM EDT

Halozyme Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
1.02B 829.25M 660.12M 443.31M
Cost of Revenue
159.42M 192.36M 139.3M 81.41M
Gross Profit
855.91M 636.89M 520.81M 361.9M
Operating Income
551.48M 337.57M 267.53M 275.9M
Interest Income
n/a n/a n/a n/a
Pretax Income
557.13M 348.33M 248.92M 248.52M
Net Income
444.09M 281.59M 202.13M 402.71M
Selling & General & Admin
154.34M 149.18M 143.53M 50.32M
Research & Development
79.05M 76.36M 66.61M 35.67M
Other Expenses
71.05M 73.77M 43.15M n/a
Operating Expenses
304.43M 299.32M 253.28M 86M
Interest Expense
18.09M 18.76M 16.95M 7.53M
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
463.85M 491.68M 392.58M 167.41M
Income Tax Expense
113.04M 66.73M 46.79M -154.19M
Shares Outstanding (Basic)
126.83M 131.93M 136.84M 140.65M
Shares Outstanding (Diluted)
129.42M 134.2M 140.61M 146.8M
EPS (Basic)
3.50 2.13 1.48 2.86
EPS (Diluted)
3.43 2.10 1.44 2.74
EBITDA
656.54M 451.95M 315.51M 259.04M
EBIT
575.23M 367.09M 265.87M 256.04M
Depreciation & Amortization
81.31M 84.86M 49.64M 3M